Nanomedicine for respiratory diseases.

Nanotechnology provides new materials in the nanometer range with many potential applications in clinical medicine and research. Due to their unique size-dependent properties nanomaterial such as nanoparticles offer the possibility to develop both new therapeutic and diagnostic tools. Thus, applied nanotechnology to medical problems--nanomedicine--can offer new concepts that are reviewed. The ability to incorporate drugs into nanosystems displays a new paradigm in pharmacotherapy that could be used for cell-targeted drug delivery. Nontargeted nanosystems such as nanocarriers that are coated with polymers or albumin and solid lipid particles have been used as transporter in vivo. However, nowadays drugs can be coupled to nanocarriers that are specific for cells and/or organs. Thus, drugs that are either trapped within the carriers or deposited in subsurface oil layers could be specifically delivered to organs, tumors and cells. These strategies can be used to concentrate drugs in selected target tissues thus minimizing systemic side effects and toxicity. In addition to these therapeutic options, nanoparticle-based "molecular" imaging displays a field in which this new technology has set the stage for an evolutionary leap in diagnostic imaging. Based on the recent progress in nanobiotechnology there is potential for nanoparticles and -systems to become useful tools as therapeutic and diagnostic tools in the near future.

[1]  James M. Wilson,et al.  Submucosal glands are the predominant site of CFTR expression in the human bronchus , 1992, Nature Genetics.

[2]  A. Vila,et al.  PEG-PLA nanoparticles as carriers for nasal vaccine delivery. , 2004, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[3]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[4]  M. Hollingsworth,et al.  MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands in human bronchial airways. , 1998, American journal of respiratory cell and molecular biology.

[5]  A. Gruber,et al.  A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma , 2004, Nature Medicine.

[6]  G. Lamblin,et al.  Heterogeneity of the carbohydrate chains of sulfated bronchial glycoproteins isolated from a patient suffering from cystic fibrosis. , 1975, The Journal of biological chemistry.

[7]  J. Sheehan,et al.  Mucins in airway secretions from healthy and chronic bronchitic subjects. , 1996, The Biochemical journal.

[8]  R. Stern,et al.  The diagnosis of cystic fibrosis. , 1997, The New England journal of medicine.

[9]  Helen M. Blau,et al.  Nuclear reprogramming: A key to stem cell function in regenerative medicine , 2004, Nature Cell Biology.

[10]  Jian Zhang,et al.  Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. , 2002, Human gene therapy.

[11]  Robert Langer,et al.  Moving smaller in drug discovery and delivery , 2002, Nature Reviews Drug Discovery.

[12]  K. Leong,et al.  Gene transfer by DNA-gelatin nanospheres. , 1999, Archives of biochemistry and biophysics.

[13]  A. Nicholson,et al.  Expression of respiratory mucins in fatal status asthmaticus and mild asthma , 2002, Histopathology.

[14]  Jack A Roth,et al.  Nanoparticle Based Systemic Gene Therapy for Lung Cancer: Molecular Mechanisms and Strategies to Suppress Nanoparticle-Mediated Inflammatory Response , 2004, Technology in cancer research & treatment.

[15]  S. Gambhir.  Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[16]  E. Veerman,et al.  MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. , 1998, The Biochemical journal.

[17]  Peter Aldhous.  Regenerative medicine: A world of difference , 2001, Nature.

[18]  M. Alonso,et al.  Nanoparticles as carriers for nasal vaccine delivery , 2005, Expert review of vaccines.

[19]  Paul A Dayton,et al.  Targeted imaging using ultrasound , 2002, Journal of magnetic resonance imaging : JMRI.

[20]  Joaquín Lamela,et al.  Airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[21]  Dagmar Högemann,et al.  "Seeing inside the body": MR imaging of gene expression , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Axel Fischer,et al.  Distribution of Respiratory Mucin Proteins in Human Nasal Mucosa , 2003, The Laryngoscope.

[23]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[24]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  M. Hodson,et al.  AEROSOL CARBENICILLIN AND GENTAMICIN TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION IN PATIENTS WITH CYSTIC FIBROSIS , 1981, The Lancet.

[26]  Daniel Todd,et al.  Immunogenicity of bovine parainfluenza type 3 virus proteins encapsulated in nanoparticle vaccines, following intranasal administration to mice. , 2003, Research in veterinary science.

[27]  R Gomeni,et al.  Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability , 1992, Antimicrobial Agents and Chemotherapy.

[28]  R. Lockey,et al.  Genetic Vaccines and Therapy , 2003 .

[29]  Dechun Li,et al.  Localization and up‐regulation of Mucin (MUC2) gene expression in human nasal biopsies of patients with cystic fibrosis , 1997, The Journal of pathology.

[30]  H. Lindgren,et al.  Mucus glycoproteins from cystic fibrotic sputum. Macromolecular properties and structural 'architecture'. , 1991, The Biochemical journal.

[31]  J. Nagy,et al.  Discovery of a potent nanoparticle P‐selectin antagonist with anti‐inflammatory effects in allergic airway disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  A. Thie,et al.  Fabrication and Biocompatibility of Carbon Nanotube-Based 3D Networks as Scaffolds for Cell Seeding and Growth , 2004 .

[33]  Erkki Ruoslahti,et al.  Nanocrystal targeting in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Kim,et al.  Targeted Molecular Imaging , 2003, Korean journal of radiology.

[35]  Rajesh Pandey,et al.  Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. , 2003, The Journal of antimicrobial chemotherapy.

[36]  K V Chace,et al.  Comparison of physicochemical properties of purified mucus glycoproteins isolated from respiratory secretions of cystic fibrosis and asthmatic patients. , 1985, Biochemistry.

[37]  Michael E Phelps,et al.  Positron emission tomography scanning: current and future applications. , 2002, Annual review of medicine.

[38]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[39]  N. Høiby,et al.  Pathogenesis of cystic fibrosis , 1993, The Lancet.

[40]  B. Ramsey,et al.  Management of pulmonary disease in patients with cystic fibrosis. , 1996, The New England journal of medicine.

[41]  F. Gage,et al.  Embryonic stem cells: staying plastic on plastic , 2004, Nature Medicine.

[42]  R. Weissleder,et al.  Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[43]  M. Corey,et al.  Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. , 1982, The Journal of pediatrics.

[44]  Y Zhang,et al.  Genotypic analysis of respiratory mucous sulfation defects in cystic fibrosis. , 1995, The Journal of clinical investigation.

[45]  Umar Mahmood,et al.  Molecular MR Imaging Probes , 2005, Proceedings of the IEEE.

[46]  D. Thornton,et al.  Mucus glycoproteins from 'normal' human tracheobronchial secretion. , 1990, The Biochemical journal.

[47]  D Honeybourne,et al.  Antibiotic penetration into lung tissues , 2004 .

[48]  R Gupta,et al.  The structure of tracheobronchial mucins from cystic fibrosis and control patients. , 1992, The Journal of biological chemistry.

[49]  T. Boat,et al.  Biochemistry of airway mucus secretions. , 1980, Federation proceedings.

[50]  K. Zaret,et al.  Regenerative medicine: Self-help for insulin cells , 2004, Nature.